The commenter, representing a global coalition of patient advocacy groups, acknowledges the benefits of the proposed program but argues it is currently ill-equipped for rare and pediatric cancers. They request further revisions to the guidance to better accommodate these specific patient communities and offer to participate in future efforts.

Concordare Trials, Inc., a clinical trial technology company, supports the Expedited IND Pilot Program and advocates for the use of structured, machine-readable protocol data to achieve the program's parallelization goals. They recommend specific technical criteria for Qualified Research Institutions (QRIs), including standards alignment with ICH M11 and CDISC USDM, and offer to share operational data and participate in technical discussions.

Dr. Jordan Despanie supports the establishment of the Expedited Investigational New Drug (IND) Acceleration Pilot Program to accelerate First-in-Human timelines and maintain U.S. biopharmaceutical competitiveness. The commenter proposes a five-pillar regulatory architecture involving Bayesian clinical trial design, AI-driven preclinical de-risking, an "Architecture of Trust" for AI governance, site-specific infrastructure, and alignment with late-stage incentives.

Dyne Therapeutics, Inc. supports the FDA's proposed Expedited Investigational New Drug Pilot Program aimed at shortening the time to first-in-human clinical study initiation. They recommend specific criteria for qualifying Qualified Review Institutions (QRIs), emphasizing expertise in rare diseases and complex modalities, while ensuring sponsors retain regulatory strategy ownership and that success is measured by end-to-end acceleration.

Ocugen, Inc., a biotechnology company, supports the FDA's Expedited Investigational New Drug Pilot Program but argues it should be further streamlined by adopting a notification-based approach modeled after Australia's Therapeutic Goods Administration (TGA) framework. They recommend specific modifications including permitting single-species toxicology data, allowing GMP-like material for Phase 1 studies, and prioritizing US-based sponsors and innovation.

Flagship Pioneering, a venture creation and innovation firm, supports the FDA's proposed Expedited Investigational New Drug (IND) Pilot Program to modernize the U.S. system and remain globally competitive. They advocate for specific improvements, including funding for Qualified Research Institutions (QRIs), modular review processes, and alignment with international models like Australia's clinical trial notification pathway.

ICON Clinical Research, LLC expresses strong support for the FDA's Expedited Investigational New Drug Pilot Program, noting its potential to improve IND submission quality and efficiency. The company recommends specific criteria for Qualified Research Institution (QRI) qualification, the use of structured risk-benefit assessment frameworks, and the development of standardized review templates and manuals.

Jerry Henley, CEO of Azunic AI, expresses full support for the Expedited IND initiative and proposes a collaborative partnership with Australian ethics committees and regulatory experts. He suggests establishing a bilateral relationship to exchange data and operational expertise to ensure the pilot's success and avoid potential risks.

Dr. Ansuman Satpathy, a physician-scientist and biotechnology entrepreneur, supports the proposed Expedited Investigational New Drug (IND) Pilot Program. He recommends specific structural improvements, such as allowing QRI consortia, and suggests a future phase where proven QRIs could be granted greater decision-making authority to further accelerate drug development.

GATC Health Corp., a tech-bio company, strongly supports the FDA's AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program. They argue that the pilot should focus on using AI to improve decision quality—such as patient selection, dose optimization, and safety prediction—rather than just operational efficiency, while emphasizing rigorous validation, human oversight, and trustworthy AI principles.